Company

Solid Biosciences Inc.

Headquarters: Cambridge, MA, United States

Employees: 70

CEO: Mr. Ilan Ganot

NASDAQ: SLDB -3.72%

Market Cap

$111.6 Million

USD as of Jan. 1, 2024

Market Cap History

Solid Biosciences Inc. market capitalization over time

Evolution of Solid Biosciences Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Solid Biosciences Inc.

Detailed Description

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Solid Biosciences Inc. has the following listings and related stock indices.


Stock: NASDAQ: SLDB wb_incandescent

Details

Headquarters:

141 Portland Street

Fifth Floor

Cambridge, MA 02139

United States

Phone: 617 337 4680